Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 23469661)

1.

[Intermittent androgen deprivation for aggressive prostate cancer: 8 years of clinical experience].

Shao Q, Zhang FB, Zhu XD, Du Y, Tian Y.

Zhonghua Nan Ke Xue. 2013 Jan;19(1):44-8. Chinese.

PMID:
23469661
2.

[Hormonal therapy for prostate cancer: methods and prognosis].

Huang BX, Su HC, Cao WL, Sun FK.

Zhonghua Nan Ke Xue. 2013 Sep;19(9):815-9. Chinese.

PMID:
24386861
3.

Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer.

Grossfeld GD, Chaudhary UB, Reese DM, Carroll PR, Small EJ.

Urology. 2001 Aug;58(2):240-5.

PMID:
11489710
4.

Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer.

Youssef E, Tekyi-Mensah S, Hart K, Bolton S, Forman J.

Am J Clin Oncol. 2003 Oct;26(5):e119-23.

PMID:
14528085
5.

Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial.

de Leval J, Boca P, Yousef E, Nicolas H, Jeukenne M, Seidel L, Bouffioux C, Coppens L, Bonnet P, Andrianne R, Wlatregny D.

Clin Prostate Cancer. 2002 Dec;1(3):163-71.

PMID:
15046691
6.

Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience.

Pether M, Goldenberg SL, Bhagirath K, Gleave M.

Can J Urol. 2003 Apr;10(2):1809-14.

PMID:
12773232
7.
8.

A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: oncological results.

Prapotnich D, Cathelineau X, Rozet F, Barret E, Mombet A, Cathala N, Sanchez-Salas RE, Vallancien G.

World J Urol. 2009 Oct;27(5):627-35. doi: 10.1007/s00345-009-0393-1. Epub 2009 Feb 27.

PMID:
19247669
9.

Intermittent androgen deprivation for clinically localized prostate cancer: initial experience.

Grossfeld GD, Small EJ, Carroll PR.

Urology. 1998 Jan;51(1):137-44.

PMID:
9457309
10.

Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer.

Kaneko Y, Maekawa S, Arakaki R, Okada Y, Terada N, Nishimura K.

Hinyokika Kiyo. 2006 Apr;52(4):259-64.

PMID:
16686352
11.

Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.

Mottet N, Van Damme J, Loulidi S, Russel C, Leitenberger A, Wolff JM; TAP22 Investigators Group.

BJU Int. 2012 Nov;110(9):1262-9. doi: 10.1111/j.1464-410X.2012.11120.x. Epub 2012 Apr 13.

PMID:
22502816
12.

Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy.

Tunn UW, Canepa G, Kochanowsky A, Kienle E.

Prostate Cancer Prostatic Dis. 2012 Sep;15(3):296-302.

PMID:
22733160
13.

[Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study].

Maekawa S, Maegawa M, Ushida H, Inoue K, Kaneko Y, Ohmori K, Nishimura K.

Hinyokika Kiyo. 2001 Aug;47(8):553-5. Japanese.

PMID:
11579594
14.

The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer.

Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL; FinnProstate Group.

J Urol. 2012 Jun;187(6):2074-81. doi: 10.1016/j.juro.2012.01.122. Epub 2012 Apr 11.

PMID:
22498230
15.

Intermittent complete androgen blockade in metastatic prostate cancer.

Rambeaud JJ.

Eur Urol. 1999;35 Suppl 1:32-6. Review.

PMID:
10081701
16.

Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?

Labrie F, Candas B, Gomez JL, Cusan L.

Urology. 2002 Jul;60(1):115-9.

PMID:
12100935
17.

Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer?

Mottet N, Lucas C, Sene E, Avances C, Maubach L, Wolff JM.

Urol Int. 2005;75(3):204-8.

PMID:
16215305
18.

Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.

Salonen AJ, Viitanen J, Lundstedt S, Ala-Opas M, Taari K, Tammela TL; FinnProstate Group.

J Urol. 2008 Sep;180(3):915-9; discussion 919-20. doi: 10.1016/j.juro.2008.05.009. Epub 2008 Jul 17.

PMID:
18635219
19.

Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.

Abrahamsson PA.

Eur Urol. 2010 Jan;57(1):49-59. doi: 10.1016/j.eururo.2009.07.049. Epub 2009 Aug 7. Review.

PMID:
19683858
20.

Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.

Manikandan R, Srirangam SJ, Pearson E, Brown SC, O'Reilly P, Collins GN.

Urol Int. 2005;75(3):217-21.

PMID:
16215308
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk